G R Infraprojects Limited (BOM:543317)
India · Delayed Price · Currency is INR 1,221.70
-14.00 (-1.13%)
At close: Aug 7, 2025
Inozyme Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 10,143 | 13,236 | 14,544 | 8,319 | 9,548 | Upgrade |
Depreciation & Amortization | - | 2,446 | 2,432 | 2,444 | 2,801 | 2,252 | Upgrade |
Other Amortization | - | - | 10.71 | 12.33 | 15.61 | 18.95 | Upgrade |
Loss (Gain) From Sale of Assets | - | -432.16 | -3,137 | -74.17 | 12.61 | 34.45 | Upgrade |
Loss (Gain) From Sale of Investments | - | -203.76 | -70.74 | -44.12 | -18.47 | -7.91 | Upgrade |
Loss (Gain) on Equity Investments | - | -2,098 | -64.49 | - | - | - | Upgrade |
Stock-Based Compensation | - | 38.91 | 71.35 | - | - | - | Upgrade |
Provision & Write-off of Bad Debts | - | 1.16 | 577.52 | 536.92 | 532.28 | - | Upgrade |
Other Operating Activities | - | -1,930 | 15,566 | 17,717 | 3,302 | 4,034 | Upgrade |
Change in Accounts Receivable | - | 258.01 | 571.61 | 704.04 | -1,173 | -1,872 | Upgrade |
Change in Inventory | - | 2,296 | 1,166 | 1,375 | 366.24 | -2,901 | Upgrade |
Change in Accounts Payable | - | 868.05 | -165.3 | 1,250 | -84.39 | 1,683 | Upgrade |
Change in Other Net Operating Assets | - | -31,704 | -46,119 | -42,100 | -12,408 | -17,358 | Upgrade |
Operating Cash Flow | - | -20,316 | -15,924 | -3,635 | 1,665 | -4,568 | Upgrade |
Capital Expenditures | - | -1,537 | -1,181 | -2,975 | -4,346 | -5,164 | Upgrade |
Sale of Property, Plant & Equipment | - | 1,029 | 233.61 | 280.41 | 119.81 | 74.87 | Upgrade |
Cash Acquisitions | - | -180.67 | - | - | - | - | Upgrade |
Divestitures | - | 5,038 | 111.66 | - | 2.24 | - | Upgrade |
Sale (Purchase) of Intangibles | - | -21.78 | - | - | - | - | Upgrade |
Investment in Securities | - | -4,522 | 2,312 | -3,360 | 1,292 | -2,656 | Upgrade |
Other Investing Activities | - | 4,521 | 8,001 | 5,965 | 360.95 | 392.62 | Upgrade |
Investing Cash Flow | - | 4,327 | 9,476 | -88.49 | -2,571 | -7,353 | Upgrade |
Short-Term Debt Issued | - | - | - | 1,337 | - | 2,575 | Upgrade |
Long-Term Debt Issued | - | 27,678 | 24,829 | 9,890 | 16,319 | 16,502 | Upgrade |
Total Debt Issued | - | 27,678 | 24,829 | 11,227 | 16,319 | 19,076 | Upgrade |
Short-Term Debt Repaid | - | -500 | -1,381 | - | -2,334 | - | Upgrade |
Long-Term Debt Repaid | - | -4,364 | -6,708 | -6,828 | -7,054 | -5,867 | Upgrade |
Total Debt Repaid | - | -4,864 | -8,089 | -6,828 | -9,387 | -5,867 | Upgrade |
Net Debt Issued (Repaid) | - | 22,813 | 16,740 | 4,399 | 6,932 | 13,209 | Upgrade |
Issuance of Common Stock | - | 51.3 | - | - | - | - | Upgrade |
Repurchase of Common Stock | - | - | - | - | - | -13.8 | Upgrade |
Common Dividends Paid | - | -1,209 | - | - | - | - | Upgrade |
Other Financing Activities | - | -4,411 | -5,538 | -4,603 | -3,823 | -3,476 | Upgrade |
Financing Cash Flow | - | 17,245 | 11,203 | -203.37 | 3,108 | 9,719 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | -1,528 | - | - | - | Upgrade |
Net Cash Flow | - | 1,256 | 3,227 | -3,927 | 2,201 | -2,202 | Upgrade |
Free Cash Flow | - | -21,853 | -17,105 | -6,609 | -2,682 | -9,732 | Upgrade |
Free Cash Flow Margin | - | -29.55% | -19.05% | -6.97% | -3.17% | -12.41% | Upgrade |
Free Cash Flow Per Share | - | -225.80 | -176.87 | -68.36 | -27.74 | -100.38 | Upgrade |
Cash Interest Paid | - | 4,411 | 5,538 | 4,603 | 3,823 | 3,476 | Upgrade |
Cash Income Tax Paid | - | 2,552 | 3,269 | 3,572 | 3,120 | 2,848 | Upgrade |
Levered Free Cash Flow | - | 19,560 | 12,604 | 3,810 | -2,562 | 1,519 | Upgrade |
Unlevered Free Cash Flow | - | 22,361 | 15,988 | 6,478 | -209.85 | 3,624 | Upgrade |
Updated Feb 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.